🚨MIGRAINE POLICY ALERT: EMHA is launching the European Roadmap on Migraine. This is our definitive strategic document to force political prioritisation of a condition that affects 41M EU adults and costs €111 BILLION in indirect costs. #MigraineRoadmap #EUHealth

Review the full Roadmap and join us in championing this change ➡️ https://t.co/8DFdzLoFAv #MigraineRoadmap #EUHealth

Why the urgency? Migraine is the 2nd leading cause of disability overall24. Yet, patients face barriers from restrictive reimbursement to lack of institutional awareness25. This inequity fuels a massive economic and human cost. #MigraineRoadmap #EUHealth

This Roadmap is built on hard evidence and consensus. It synthesises the conclusions from the "Breaking the Silence on Migraine" event (EP, 11 June 2025), uniting 34 patient advocacy groups across 20+ countries. This is a global call for local change. #MigraineRoadmap #EUHealth

Vielen Dank an @emhalliance über 35 Patientenverbänden weltweit zusammenzubringen. Es war sehr bereichernd, Erfahrungen auszutauschen und voneinander zu lernen. 👉Wir sind nicht allein mit unseren #Migräne-Problemen. ➡️Es ist eine Freude, Teil dieser Community zu sein #MHIPAS2025

@EMHAlliance …We are committed to supporting the migraine community through advocacy work to help recognize migraine as a neurological disease, improve timely screening and diagnosis, improve access to treatment.”]

@EMHAlliance [Video description: On-screen text reads: “Migraine is a debilitating neurological disease estimated to affect one billion people worldwide…

📢 EBC endorses the @EMHAlliance White Paper on Strategic Advocacy Framework to Improve Migraine Care and Support! Policymakers have a unique opportunity to implement changes that can significantly improve the lives of people with #migraine. 🔗 https://t.co/1HgONUCFk5

Today we had the honour of hearing Prof. Edvinsson and Prof. @petergoadsby, Brain Prize Winners of 2021 among many other achievements. Thank you for enlightening and giving hope to the 52 patient representatives who have come from 29 different countries worldwide #MHIPAS2025

Today we are honored to listen to Prof. @petergoadsby Goadsby once more, as he shares insights on the International Classification of Headache Disorders. What’s next for improving migraine diagnosis? Are we finally making meaningful advances? #MHIPAS2025

Prof. Lars Edvinsson expands on the studies pointing towards a dysregulated brain being the root cause for migraine, which leaves us with a question: How does the nerve responsible for activating the pain? #MHIPAS2025

On June 12th, we are honored to announce a scientific program that will go on for the whole day, followed by a celebration commemorating the 20th anniversary of EMHA’s fight to raise awareness for migraine. On June 13th, we will close the event with the key outcomes #MHIPAS2025

Today, alongside worldwide patient associations, leading experts and policymakers, will meet at the European Parliament to advocate for the full inclusion of migraine in the EU’s forthcoming Neurological Health Strategy.#MHIPAS2025

Ready to make a difference in⁣ migraine care? EMHA’s White Paper advocates on 3 urgent priorities to improve⁣ the lives of people living with this condition.⁣ ⁣👉This initiative was made possible thanks to @abbvie ´s collaboration ⁣ https://t.co/bjWy8VrV8d #MHIPAS2025

See you soon at #MHIPAS2025, an event that will bring together science, politicians, industry and patients 🤝 that will highlight key milestones, both in terms of progress and restrictions in different countries.

Want to help transform migraine care in your country?⁣ Discover EMHA’s White Paper and explore how we can turn dialogue into action, together with key stakeholders to improve access to care.⁣ ⁣This initiative was made possible thanks to @abbvie https://t.co/bjWy8VrV8d

We would like to welcome Wellvo as a collaborator in our #MFW project, which aims to create an empathetic and flexible workplace for people who suffer from migraine.

One in seven workers suffers from migraine, a condition that completely affects their ability to concentrate and do their job. This is why we, today, the worker’s day, we want to thank the more than 40 companies that have joined our "Migraine Friendly Workplace" project🙌🏻

Dr. Karsan, postdoctoral researcher within the Headache Group at King's College London, shares a study on novel treatments such as Ubrogepant for the acute treatment of migraine. If you are an MFW member, you can access the full content👉 https://t.co/6kly6JAJDS ⁣⁣⁣⁣⁣

Pope Francis welcomed EMHA, wanted to learn more about migraine and sent a blessing to all those affected. We will always be grateful. May he rest in peace.